What is Zacks Research’s Estimate for Omnicell Q2 Earnings?

Omnicell, Inc. (NASDAQ:OMCL) – Analysts at Zacks Research lowered their Q2 2026 earnings per share estimates for shares of Omnicell in a note issued to investors on Thursday, March 5th. Zacks Research analyst Team now forecasts that the company will post earnings of $0.19 per share for the quarter, down from their prior forecast of $0.20. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Omnicell’s current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell’s Q3 2026 earnings at $0.26 EPS, Q4 2026 earnings at $0.29 EPS and Q3 2027 earnings at $0.28 EPS.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, February 5th. The company reported $0.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.07). Omnicell had a return on equity of 3.00% and a net margin of 0.17%.The business had revenue of $313.98 million during the quarter, compared to analysts’ expectations of $313.36 million. During the same quarter last year, the business posted $0.60 EPS. The company’s quarterly revenue was up 2.3% on a year-over-year basis. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS.

A number of other equities analysts have also recently commented on the stock. Benchmark boosted their price target on shares of Omnicell from $50.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, February 2nd. Piper Sandler reaffirmed an “overweight” rating and set a $49.00 price objective (down from $63.00) on shares of Omnicell in a report on Friday, February 6th. KeyCorp upgraded shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 target price for the company in a research report on Wednesday, January 7th. Wells Fargo & Company increased their target price on Omnicell from $43.00 to $52.00 and gave the company an “overweight” rating in a research note on Monday, January 5th. Finally, Weiss Ratings downgraded Omnicell from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, March 2nd. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $54.50.

Omnicell Trading Down 2.1%

Shares of OMCL opened at $38.99 on Monday. The firm’s 50 day simple moving average is $44.34 and its 200 day simple moving average is $38.45. The company has a market capitalization of $1.77 billion, a P/E ratio of 974.99, a P/E/G ratio of 1.43 and a beta of 0.79. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.43 and a quick ratio of 1.22. Omnicell has a 1-year low of $22.66 and a 1-year high of $55.00.

Insider Buying and Selling at Omnicell

In related news, EVP Corey J. Manley sold 6,106 shares of Omnicell stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $49.90, for a total value of $304,689.40. Following the transaction, the executive vice president owned 91,674 shares in the company, valued at $4,574,532.60. This trade represents a 6.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.52% of the company’s stock.

Institutional Trading of Omnicell

Several institutional investors have recently added to or reduced their stakes in the business. Cerity Partners LLC boosted its stake in Omnicell by 4.9% during the 4th quarter. Cerity Partners LLC now owns 7,613 shares of the company’s stock worth $345,000 after purchasing an additional 354 shares during the period. SG Americas Securities LLC increased its stake in Omnicell by 6.6% in the third quarter. SG Americas Securities LLC now owns 6,433 shares of the company’s stock valued at $196,000 after purchasing an additional 401 shares during the period. Thrivent Financial for Lutherans raised its holdings in shares of Omnicell by 1.2% in the second quarter. Thrivent Financial for Lutherans now owns 34,445 shares of the company’s stock valued at $1,013,000 after buying an additional 424 shares during the last quarter. Martin & Co. Inc. TN raised its holdings in shares of Omnicell by 0.4% in the third quarter. Martin & Co. Inc. TN now owns 121,720 shares of the company’s stock valued at $3,706,000 after buying an additional 443 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of Omnicell by 0.3% during the third quarter. Legal & General Group Plc now owns 158,399 shares of the company’s stock worth $4,823,000 after buying an additional 448 shares during the period. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.